FREMONT, Calif. , Sept. 18, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the appointment of Dushyant Pathak , Ph.D., as senior vice president of business development. “We are pleased to welcome Dushyant, who brings
- Repeated Dosing of Qtrypta Over the Course of One Year Reaffirms Qtrypta is Effective and Well-Tolerated as an Acute Treatment for Migraine - - Efficacy and Safety Profile Consistent in Sub Analyses of Patients Taking Concurrent Medications- -Company is Preparing for a New Drug Application (NDA)
FREMONT, Calif. , Sept. 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that its chairman, president and chief executive officer, John Walker , will present a company overview at the H.C.
Oral presentation of the safety and efficacy of Qtrypta TM in a long-term safety study for the acute treatment of migraine. Poster on the results of patients’ freedom from pain and most bothersome symptom when taking Qtrypta concurrently with prophylactic anti-CGRP antibodies.
Conference call scheduled for 1:30 p.m. PT today FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced financial results for the second quarter ended June 30, 2019 , as well as recent business
FREMONT, Calif. , Aug. 14, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that the Company has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration ( FDA ) to initiate a Phase
FREMONT, Calif. , Aug. 07, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that it will host a conference call and webcast on Wednesday, August 14, 2019 at 4:30 p.m. ET to discuss results for the second quarter of 2019
Migraine Assessment of Current Therapy (or Migraine-ACT) Scores Highlight the Effectiveness of Qtrypta in Treating Migraines FREMONT, Calif. , July 15, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced the presentation of
FREMONT, Calif. , July 03, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that Hayley Lewis , senior vice president of operations at Zosano Pharma , will be presenting a keynote speech entitled, “A Novel Intracutaneous
FREMONT, Calif. , July 01, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage biopharmaceutical company, today announced that a poster and e-poster describing Migraine-ACT scores, or measures of patient satisfaction with the management of their migraines, following
